Multi-institutional Phase 2/3 Trial of Valproic Acid in Patients With Moderate to Severe Traumatic Brain Injury
Multi-institutional Phase 2/3 Trial of Valproic Acid in Patients With Moderate to Severe Traumatic Brain Injury
The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI).
Patients with moderate to severe TBI will randomly receive either:
The specific aim is to determine whether giving VPA at either a 50 mg/kg dose or a 100 mg/kg is safe (as measured by adverse events after treatment) in patients with moderate to severe TBI due to brain bruises.
Inclusion Criteria:
Exclusion Criteria:
Hasan.Alam@nm.org312-926-4962
nicole.meredyth@nm.org312-694-4867
Birmingham, Alabama 35294, United States
jrodgers@uabmc.edu205-515-3590
rscarlson@arizona.edu520-626-2876
monica.wong@med.usc.edu323-409-8597
slnichols@health.ucdavis.edu
underwos@ohsu.edu503-494-5400
Heather.white@vumc.org615-421-2996
katherine.bosler@utsowthwestern.edu
mrundell@mcw.edu